Global Diabetic Nephropathy Market Outlook to 2022 with AstraZeneca, Merck and Sanofi Dominating - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--Jan 8, 2019--The “Global Diabetic Nephropathy Market 2018-2022” report has been added to ResearchAndMarkets.com’s offering.
The diabetic nephropathy market will register a CAGR of almost 34% by 2022.
Rise in incidence of diabetes to push growth in the market
Globally, there has been a rise in the incidence and prevalence of diabetes, which has resulted in the occurrence of chronic kidney disease in patients.
Increasing incidence of diabetic nephropathy among diabetic patients
The incidence of diabetic nephropathy was observed to be much higher in freshly diagnosed cases of type 2 diabetes patients. The factors associated with the rise of incidence of nephropathy are hypertension, hypercholesterolemia, and obesity.
Growing economic burden of diabetic nephropathy
Diabetic nephropathy is a complication associated with diabetes mellitus. The cost associated with diabetic nephropathy increases gradually with the progression of disease due to the associated cost drivers such as dialysis and hospitalization.
Key PlayersAstraZeneca Merck Sanofi
PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
PART 03: RESEARCH METHODOLOGY
PART 04: MARKET LANDSCAPEMarket ecosystem Market characteristics Market segmentation analysis
PART 05: PIPELINE ANALYSIS
PART 06: MARKET SIZINGMarket definition Market sizing 2017 Market size and forecast 2017-2022
PART 07: FIVE FORCES ANALYSIS
PART 08: MARKET SEGMENTATION BY DRUG CLASSSegmentation by drug class Comparison by drug class ARBs - Market size and forecast 2017-2022 ACE inhibitors - Market size and forecast 2017-2022 Others - Market size and forecast 2017-2022 Market opportunity by drug class
PART 09: MARKET SEGMENTATION BY TYPE OF DISEASE
PART 10: CUSTOMER LANDSCAPE
PART 11: REGIONAL LANDSCAPEGeographical segmentation Regional comparison Americas - Market size and forecast 2017-2022 EMEA - Market size and forecast 2017-2022 APAC - Market size and forecast 2017-2022 Market opportunity
PART 12: DECISION FRAMEWORK
PART 13: DRIVERS AND CHALLENGES
PART 14: MARKET TRENDSRise in incidence of diabetes Increase in diabetic nephropathy-related cardiovascular mortality and end-stage renal disease Multidisciplinary approach for the management of diabetic nephropathy
PART 15: VENDOR LANDSCAPEOverview Landscape disruption
PART 16: VENDOR ANALYSISVendors covered Vendor classification Market positioning of vendors AstraZeneca Merck Sanofi
For more information about this report visit https://www.researchandmarkets.com/research/7ccgpp/global_diabetic?w=4
View source version on businesswire.com:https://www.businesswire.com/news/home/20190108005612/en/
Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics:Liver and Kidney Disorders Drugs,Endocrine and Metabolic Disorders Drugs,Urology and Nephrology
INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL
SOURCE: Research and Markets
Copyright Business Wire 2019.
PUB: 01/08/2019 08:43 AM/DISC: 01/08/2019 08:43 AM